GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaleaf Holdings Inc (OTCPK:CURLF) » Definitions » Gross Profit

Curaleaf Holdings (Curaleaf Holdings) Gross Profit : $614 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Curaleaf Holdings Gross Profit?

Curaleaf Holdings's gross profit for the three months ended in Mar. 2024 was $161 Mil. Curaleaf Holdings's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $614 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Curaleaf Holdings's gross profit for the three months ended in Mar. 2024 was $161 Mil. Curaleaf Holdings's Revenue for the three months ended in Mar. 2024 was $339 Mil. Therefore, Curaleaf Holdings's Gross Margin % for the quarter that ended in Mar. 2024 was 47.47%.

Curaleaf Holdings had a gross margin of 47.47% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 10 years, the highest Gross Margin % of Curaleaf Holdings was 80.76%. The lowest was 45.27%. And the median was 60.07%.

Warning Sign:

Curaleaf Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -6.3%.


Curaleaf Holdings Gross Profit Historical Data

The historical data trend for Curaleaf Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaleaf Holdings Gross Profit Chart

Curaleaf Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 141.61 390.51 677.95 626.42 614.45

Curaleaf Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 160.44 146.52 150.05 156.19 160.90

Competitive Comparison of Curaleaf Holdings's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curaleaf Holdings's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Curaleaf Holdings's Gross Profit falls into.



Curaleaf Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Curaleaf Holdings's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1346.632 - 732.183
=614

Curaleaf Holdings's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=338.932 - 178.028
=161

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $614 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Curaleaf Holdings's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=161 / 338.932
=47.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Curaleaf Holdings  (OTCPK:CURLF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Curaleaf Holdings had a gross margin of 47.47% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Curaleaf Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Curaleaf Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Curaleaf Holdings (Curaleaf Holdings) Business Description

Traded in Other Exchanges
Address
420 Lexington Avenue, Suite 2035, New York, NY, USA, 10170-0052
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 18 states. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.